Track topics on Twitter Track topics that are important to you
This will be a 36-week, randomized, double-blind, parallel group study comparing the effects of tadalafil monotherapy, ambrisentan monotherapy and combination therapy with tadalafil and ambrisentan in patients with PAH-SSc. Standard outcome measures such as six-minute walk distance (6MWD), NYHA classification, and hemodynamic measurements will be assessed, as well as novel functional measures of RV-PV function including the transthoracic echocardiogram parameter tricuspid annular plane systolic ejection (TAPSE), contrast-enhanced cardiac MRI and heart rate variability assessed by Holter monitoring. This design (excluding a placebo-placebo arm) was selected for ethical concerns and to provide optimal efficiency and active therapy to all study subjects. It also allows for comparisons between the two monotherapies and with combination therapy.
Pulmonary Arterial Hypertension (PAH) includes a heterogeneous group of clinical entities sharing similar clinical and pathological features that have been subcategorized as idiopathic PAH (IPAH, formerly known as "primary pulmonary hypertension" or PPH), familial PAH, pulmonary hypertension related to connective tissue diseases (such as systemic sclerosis), portopulmonary hypertension and pulmonary hypertension related to HIV infection, drugs and toxins (10). PAH is clinically defined by a resting mean pulmonary artery pressure ≥ 25 mmHg and pulmonary artery wedge pressure ≤ 15 mmHg in the absence of left heart disease, underlying parenchymal lung disease, thromboembolic disease or other causes of pulmonary hypertension.
PAH is characterized by increased pulmonary vascular resistance due to remodeling and occlusion of the pulmonary arterioles. Left untreated, PAH leads irremediably to right ventricular (RV) hypertrophy, pressure overload and dilation resulting in death within 2-3 years (11). For the past two decades, it has been appreciated that the integrity of the RV function, rather than the degree of pulmonary vascular injury, is the major determinant of symptoms and mortality in patients with PAH. RV dysfunction at time of presentation, as reflected by an elevation in right atrial pressure (RAP), the presence of pericardial effusion or depressed cardiac output (CO), is a powerful prognosticator of death (12).
Current PAH therapies consist of prostacyclin analogues, endothelin receptor antagonists (ETRA) and phosphodiesterase type V (PDE V) inhibitors (13). All have been shown to be effective in improving exercise capacity as measured by the 6 MWD in short term (12 - 16 week) randomized, placebo-controlled clinical trials. However, the clinical response is highly variable and mortality remains high (14). Moreover, the majority of subjects enrolled in these trials have had IPAH. Over the past 10 years, the Johns Hopkins Pulmonary Hypertension Program and Scleroderma Center have worked closely to address the daunting clinical challenge of PAH associated with scleroderma or systemic sclerosis (PAH-SSc). Previous work from our group (15;16) and others (17-19) has clearly demonstrated a markedly worse prognosis in PAH-SSc compared with IPAH despite similar treatments. An intriguing and consistent finding when comparing these two groups is that whereas mPAP is, on average, lower in PAH-SSc, markers of RV dysfunction (e.g. CO and RAP) are similar, raising the possibility of maladaptive RV response to pressure overload and/or intrinsic myocardial disease. Current PAH therapies target pathways that have been implicated in the remodeling of the pulmonary vasculature (PV). However, there is no clear evidence that these therapies have altered PV and/or RV remodeling or offered significant beneficial effects in patients with PAH-SSc in whom mortality remains exceedingly high. In addition, their effects on RV dysfunction and RV-PV interaction remain poorly characterized.
We hypothesize that improvement in PAH-SSc will only be achieved with therapy directly targeted at RV-PV dysfunction. Sildenafil and tadalafil inhibit phosphodiesterase type 5 (PDE5) which is abundant in the lung and is the main enzyme responsible for cGMP hydrolysis. The resulting increase in cGMP probably mediates the relaxant and anti-hypertrophic actions of nitric oxide and natriuretic peptides in vascular tissues, and exerts a direct anti-hypertrophic action on cardiac muscle as demonstrated in compelling preliminary experiments by investigators of the NHLBI-funded Hopkins Scientific Center of Clinically Oriented Research (SCCOR) in Pulmonary Vascular Disease. In these experiments, sildenafil was capable of preventing and reversing RV hypertrophy and dysfunction in a model of pulmonary artery banding, similar to its effects on the left ventricle with aortic banding (20), indicating a direct beneficial action on RV remodeling.
Both sildenafil (21) and tadalafil (22) have been demonstrated to be effective in PAH and are FDA approved for this indication. The endothelin-receptor antagonists, bosentan (23) and ambrisentan (24), are also FDA-labeled for this indication and represent alternative options for oral therapy of PAH (25). A small randomized study comparing sildenafil with bosentan suggested that sildenafil was superior in reducing RV mass and improving exercise capacity in patients with PAH (26). Recently, the results of a large multi-center randomized, controlled trial of tadalafil therapy for PAH have been presented. The data indicate, that similar to sildenafil, tadalafil at doses of 20 and 40 mg per day, improved exercise capacity. In addition, tadalafil 40 mg per day improved pulmonary hemodynamics, quality of life and reduced the incidence of clinical worsening.
This study aims to compare the effects of tadalafil therapy, ambrisentan therapy and the combination of both agents in PAH-SSc on PVR and RV mass. It will also assess novel markers of RV function by cardiac MRI and echocardiography, as well as the conventional endpoints, including 6 MWD and functional class. The trial is unique in that it will enroll only PAH-SSc patients, the PAH subgroup with the poorest outcomes and will be considerably longer in duration (36 weeks) than previous studies. In addition, the effects of first line combination therapy with an ETRA/PDE V inhibitor will be compared with single agent regimens.
Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Pulmonary Arterial Hypertension
Tadalafil monotherapy, Ambrisentan monotherapy, tadalafil and ambrisentan
Johns Hopkins University
Published on BioPortfolio: 2014-08-27T03:16:54-0400
The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in...
This is a multicenter, randomized (2:1 oral treprostinil: placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are currently receivin...
To evaluate the change from baseline in pulmonary vascular resistance (PVR), and other hemodynamic parameters, following the addition of ambrisentan to background phosphodiesterase type-5 ...
The purpose of this study is to evaluate the efficacy and safety of the combination of ambrisentan and tadalafil in reducing mPAP to below 35mmHg in patients with moderate to severe Portop...
This study is designed to understand the relative bioavailability (proportion of the administered dose that is absorbed into the bloodstream) of several fixed dose combinations (FDCs) tabl...
An orodispersible film (ODF) of tadalafil may provide increased convenience for erectile dysfunction (ED) patients as compared to conventional tablet formulations. In this study, we aimed to compare t...
Cyclic GMP (cGMP) is an important intracellular regulator of endochondral bone growth and skeletal remodeling. Tadalafil, an inhibitor of the type 5 phosphodiesterase (PDE5) that specifically hydrolyz...
The approval of macitentan has increased the number of pharmacological treatments of pulmonary arterial hypertension (PAH). Here, we review the effect on PAH of macitentan compared to other endothelin...
To evaluate protective effects of darbepoetin and tadalafil against ischemiareperfusion injury in ipsilateral and contralateral testicle.
A novel tadalafil analogue, which exhibits similarity to 2-hydroxypropylnortadalafil, was found in dietary supplements using adulterants screening and isolated using column chromatography. By using ex...
A carboline derivative and PHOSPHODIESTERASE 5 INHIBITOR that is used primarily to treat ERECTILE DYSFUNCTION; BENIGN PROSTATIC HYPERPLASIA and PRIMARY PULMONARY HYPERTENSION.
Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies. (Campbell's Psychiatric Dictionary, 9th ed.)
A malformation of the heart in which the embryonic common PULMONARY VEIN was not incorporated into the LEFT ATRIUM leaving behind a perforated fibromuscular membrane bisecting the left atrium, a three-atrium heart. The opening between the two left atrium sections determines the degree of obstruction to pulmonary venous return, pulmonary venous and pulmonary arterial hypertension.
A respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep.
A congenital anomaly caused by the failed development of TRUNCUS ARTERIOSUS into separate AORTA and PULMONARY ARTERY. It is characterized by a single arterial trunk that forms the outlet for both HEART VENTRICLES and gives rise to the systemic, pulmonary, and coronary arteries. It is always accompanied by a ventricular septal defect.
Erectile dysfunction (ED or impotence) is the inability to get and maintain an erection that is sufficient for satisfactory sexual intercourse, and affects half of all men between the ages of 40 to 70. The causes of ED can be both physical and psycholo...
Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of affected individuals. Symptoms can range from mild breathles...